Not a good buy right now for an impatient entry: the stock is still in a broader downtrend (bearish moving-average stack) and there is no Intellectia timing signal to justify chasing today’s pop.
Options positioning is very bullish (calls dominate), but implied volatility is extremely elevated—often meaning the market is already pricing a catalyst, reducing the edge of buying here.
Wall Street targets imply large upside, but the company’s latest reported quarter still shows very weak bottom-line quality (large net loss), making near-term outcomes more binary into the 2026-02-26 earnings.
Trend/structure: Bearish (SMA_200 > SMA_20 > SMA_5), suggesting rallies can still be sold into.
Momentum: MACD histogram -0.005 (below 0) but negatively contracting → downside momentum is fading, consistent with a short-term stabilization attempt.
RSI(6)=52.8: Neutral, no clear overbought/oversold edge.
Levels: Pivot 22.634 is the key near-term line; price 22.98 is slightly above it. Upside resistance at R1 23.956 then R2 24.772; support at S1 21.313 then S2 20.496.
Near-term pattern stats (similar candles): modest expected drift (+0.85% 1-week, +1.81% 1-month), not strong enough to override the broader bearish MA setup.
Activity: Today’s volume 224 with volume vs 30-day avg at ~251.7% → attention is elevated.
Volatility: IV 30D ~66% vs historical vol ~53.7%; IV percentile 94.82 → options are expensive and the market is pricing elevated move risk (often around events).
Interpretation: Bullish sentiment is clear, but high IV suggests the “easy” upside may already be priced in; timing risk is higher into the next catalyst.
Technical Summary
Sell
8
Buy
5
Positive Catalysts
could re-rate the stock if margins/organic growth surprise positively.
Gross margin: 52.23%, up 8.29% YoY (improving profitability at the gross level).
Bottom line: Net income -571.1M and EPS -9.99 (both improved YoY but still extremely negative) → earnings quality remains the key issue to monitor into the next report.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent tone: Generally bullish (Buy/Outperform initiations and reiterations), but price targets have been trimmed by several firms (e.g., Evercore 44→40; Canaccord 58→50; Baird 50→45), signaling optimism with tempered near-term expectations.
Latest actions: BTIG initiated Buy with a $41 target (2026-01-06); Evercore kept Outperform with $40 target (2026-01-05).
Wall Street pros: Underappreciated orthopedics platform, improving profile, potential multiple re-rate if execution continues.
Wall Street cons: Concerns around scaling, exposure perceptions (tariffs/mature markets), and need to demonstrate durable cash flow/earnings consistency.
Politicians/congress: No recent congress trading data available (no signal from that channel).
Wall Street analysts forecast ENOV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENOV is 45.25 USD with a low forecast of 40 USD and a high forecast of 50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast ENOV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENOV is 45.25 USD with a low forecast of 40 USD and a high forecast of 50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 21.790
Low
40
Averages
45.25
High
50
Current: 21.790
Low
40
Averages
45.25
High
50
BTIG
Ryan Zimmerman
initiated
$41
AI Analysis
2026-01-06
Reason
BTIG
Ryan Zimmerman
Price Target
$41
AI Analysis
2026-01-06
initiated
Reason
BTIG analyst Ryan Zimmerman initiated coverage of Enovis with a Buy rating and $41 price target. The multi-segment orthopedics company offers a full continuum of orthopedic care and this strategy has consistently enabled Enovis to outperform underlying end-markets, the analyst tells investors. The firm thinks the market has written off Enovis as under-scaled, weighted towards unattractive mature markets, subject to higher tariff exposure, and lacking significant cash flow, but the firm sees an attractive entry point and an improving financial profile, the analyst added.
Evercore ISI
Outperform
downgrade
$44 -> $40
2026-01-05
Reason
Evercore ISI
Price Target
$44 -> $40
2026-01-05
downgrade
Outperform
Reason
Evercore ISI lowered the firm's price target on Enovis to $40 from $44 and keeps an Outperform rating on the shares. Recovering end markets and sector rotation have "set the stage for a 2026 Tools play," the analyst tells investors. In MedTech, the firm's survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes "have bears watching," the analyst added.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ENOV
